Comparison of biologic therapies for the treatment of psoriasis - 21/08/11
William Abramovits, MD, Texas Dermatology Research Institute, Dallas, TX, United States; Lisa Stevenson, BA, MS II
Le texte complet de cet article est disponible en PDF. P2 William Abramovits, MD, has received research support and/or is a consultant and/or lecturer for the following: Abbott Laboratories, Allergan, Inc., Amgen, Inc., Astralis, Inc., Berlex, Inc., Biogen Idec, Bradley Pharmaceuticals, Brymill Cryogenics, Centocor, Inc., Collagenex Pharmaceuticals Connetics Corporation, Corixa Corporation, Dermik Laboratories, Doak Dermatologics Ferndale Laboratories, Inc., Fujisawa Healthcare, Inc., Galderma, Genentech, Inc. GlaxoSmithKline, IDEC Corporation, Ligand Pharmaceuticals, Medicis, MedImmune, Inc. Novartis Pharmaceuticals, Otsuka Pharmaceutical, Inc., Protein Design Labs, Serono Synta Pharma, and 3M Pharmaceuticals. |
Vol 52 - N° 3S
P. P1 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?